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Background: Individualised, isotoxic, accelerated radiotherapy (INDAR) allows the delivery of high bio-
logical radiation doses, but the long-term survival associated with this approach is unknown.
Methods: Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from January 1, 2002
to December 31, 2008 were included.
Results: Patients (1002) with stage III NSCLC were diagnosed, of which 938 had T4 and/or N2–N3 disease.
Patients treated with curative intent were staged with FDG-PET scans and a contrast-enhanced CT or an
MRI of the brain. There were no shifts over time in the patient or tumour characteristics at diagnosis. The
number of stage III NSCLC patients remained stable over time, but the proportion treated with palliative
intent decreased from 47% in 2002 to 37% in 2008, and the percentage treated with chemo-radiation (RT)
increased from 24.6% in 2002 to 47.8% in 2008 (p < 0.001). The proportion of surgical patients remained
below 5%. Sequential chemotherapy and conventional RT resulted in a median and a 5-year survival of
17.5 months and 8.4%, respectively, whereas with sequential chemotherapy and INDAR this was
23.6 months and 31%, respectively (p < 0.001). Concurrent chemotherapy and INDAR was associated with
a median and 2-year survival that was not reached and 66.7%, respectively (p = 0.004).
Conclusions: The proportion of patients treated with a curative intention with chemo-RT has increased
markedly over time of observation. INDAR is associated with longer survival when compared to standard
dose RT alone given with or without chemotherapy.
 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 102 (2012) 228–233Non-small cell lung cancer (NSCLC) continues to be the leading
cause of cancer deaths [1]. Stage III, that represents approximately
one third of NSCLC cases, is heterogeneous, which is reflected in
the diversity of the treatment. Some less advanced subgroups are
treated with chemotherapy and surgery, while the majority of
cases, presenting with T4 tumours and/ or N2 or N3 disease, re-
ceive chemotherapy and radiotherapy [2]. A randomised phase III
trial that compared surgery with radiotherapy to a dose of 60 Gy
in 30 fractions in 6 weeks after induction chemotherapy in patients
with irresectable N2 disease did not find a difference in survival
between both arms [3]. Another randomised phase III study




e Ruysscher).chemo-radiation (45 Gy) vs. concurrent chemo-radiotherapy alone
(61 Gy) in NSCLC patients with resectable N2 disease, of whom 75%
had single-nodal station involvement [4]. No difference in overall
survival between both arms was observed. A meta-analysis based
on individual patient data showed that concurrent chemotherapy
and radiotherapy resulted in improved long-term survival com-
pared to sequential chemo-radiation, but at the expense of more,
but transient, oesophageal toxicity [5]. In this meta-analysis, most
patients received a radiation dose of approximately 60 Gy in 30
fractions in 6 weeks. At present, concurrent chemotherapy with
radiotherapy to a dose of 60 Gy in 30 daily fractions is thus consid-
ered to be the standard treatment, as is reflected in the standard
arm of the ongoing phase III study RTOG 0617 that investigates
whether radiation dose-escalation would be beneficial. Indeed,
indirect evidence suggests that radiation dose escalation may im-
prove survival also in the context of chemo-radiation [6]. In case
only radiotherapy is delivered, the CHART phase III study has
D. De Ruysscher et al. / Radiotherapy and Oncology 102 (2012) 228–233 229shown that accelerated radiotherapy improved survival compared
to standard fractionation [7]. These results could however not be
confirmed in the recent CHARTWEL phase III trial, although an
exploratory subgroup analysis suggested that with the addition
of chemotherapy, accelerated radiotherapy may improve survival
over standard fractionation [8]. On the other hand, a meta-analysis
based on individual patient data did show that even without sys-
temic therapy, very accelerated radiotherapy schedules improved
significantly 5-years survival rates [9].
Because of technical and biological advances of radiotherapy for
lung cancer [10], it recently became possible to individualise radio-
therapy making the delivery of iso-toxic doses feasible and prom-
ising [11]. As such, biological doses of over 80 Gy, but with toxicity
levels that are comparable to 65 Gy could be given [11]. The same
individualised approach has been investigated in concurrent
chemo-radiation schedules, with promising results as well [12].
The question still remains what the impact of these advances in
radiotherapy schedules is on a population basis, i.e. if we are able
to demonstrate an improved survival outside of clinical trials.
We therefore investigated the survival of patients with stage III
NSCLC treated with different schedules in a large, prospective
population-based cancer registry.Patients and methods
Netherlands Cancer Registry/Limburg (NCR/L)
All patients with a pathological diagnosis of NSCLC [13] in
South- and Middle Limburg and with stage III (UICC 6th Edition)
[14] from January 1, 2002 to December 31, 2008 were included.
Data were obtained from the population-based Netherlands Cancer
Registry (NCR) of the Comprehensive Cancer Centre the Nether-
lands. The NCR/L is a population-based cancer registry, which
was established in 1984 and is a department of the Comprehensive
Cancer Centre Netherlands-Location Maastricht. The NCR/L covers
the region of mid- and southern Limburg, which is situated in
the southeast of The Netherlands. On 1 January 2006, the region
covered a total of 853,553 inhabitants. In this region, Maastro clinic
is the only radiotherapy centre, in which nearly all patients need-
ing radiotherapy are being treated. Patients that were referred to
Maastro clinic from centres outside of the NCR/L were not included
in this series.
Information on topography and morphology was coded accord-
ing to the International Classification of Diseases for Oncology (3rd
ed.) [13]. Completeness of case ascertainment of the MCR is very
high; for lung cancer, this is estimated to be >95% [15].Co-morbidity
Co-morbidity of all lung cancer patients was scored using the
Charlson co-morbidity index (CCI) [16]. Co-morbidity was defined
as disease that was present at the time of diagnosis.Staging and treatment
Only patients without a malignant pleural or cardiac effusion
were offered treatment with curative intent. Patients were staged
with a whole body 18F-deoxyglucose (FDG)-Positron Emission
Tomography (PET) scan and a CT or MRI of the brain unless on a
regular CT scan of the chest and the upper abdomen metastases
were already visualised. Patients were treated according to stan-
dard regional protocols.
According to the regional guidelines, the treatment of choice for
patients with stage III (T4 and/or N2–3) NSCLC was chemo-radio-
therapy in patients with less than 10% of weight loss over the last
6 months and a WHO performance status of 0–2. Patients withT3N1M0 tumours were treated with a lobectomy and a lobe-
specific nodal dissection, followed by adjuvant chemotherapy from
2007. When a T4 tumour was defined on the basis of multiple
nodes in the same lobe and no N2 disease was found, a lobectomy
and a lobe-specific nodal dissection was done.
In practice, however, the multidisciplinary team, comprising at
least a pulmonologist specialised in lung cancer, a thoracic surgeon,
a radiation oncologist, a radiologist, a nuclear medicine specialist
and a pathologist, was left free to choose the most appropriate
treatment for an individual patient.
Sequential chemotherapy consisted or cisplatin (75 mg/m2) or
carboplatin (AUC 5) on day 1 and gemcitabine 1250 mg/m2 on
day 1 and 8. Cycles were repeated every 21 days for a total of 3 cy-
cles. The carboplatin dose in milligrams was based on the target
AUC [5] X (glomerular filtration rate +25), with the glomerular fil-
tration rate calculated according to the Cockroft–Gault formula.
Standard dose-reduction rules were applied if indicated. In non-
progressive patients (RECIST criteria) [17], based on a CT scan of
the chest, the primary tumour and the involved lymph nodes were
treated with radiotherapy. The dose was specified according to
ICRU 50 guidelines [18].
From 2002 to 2005, radiotherapy consisted of a dose of 60 Gy in
30 fractions in 6 weeks.
In the period from 2006 onwards, individualised iso-toxic accel-
erated radiotherapy (INDAR) to the primary tumour and the pre-
treatment involved lymph nodes on FDG-PET-CT scan was given
[11,19]. The mean radiation dose was 64.8 Gy given in 36 bi-daily
fractions of 1.8 Gy with at least 8 h of inter-fraction interval in an
overall treatment time of 3.6 weeks was given [11]. This is a bio-
logical equivalent of a dose of 82 Gy in 41 daily fractions given in
8.2 weeks.
Patients who were considered to be not fit enough for chemo-
therapy by the multidisciplinary team were sometimes treated
with high-dose radiotherapy. From 2002 to 2005, this was 60 Gy
given in 30 daily fractions, five times per week, and from 2006 on-
wards, INDAR was used.
From 2006, concurrent chemo-radiation was used. After 1 or 2
cycles of carboplatin-gemcitabine, concurrent cisplatin-vinorel-
bine (cisplatin 50 mg/m2 day 2 and 9, vinorelbine 20 mg/m2 day
2 and 9, cisplatin 40 mg/m2 day 23, vinorelbine 15 mg/m2 day 23
and 30; day 1 is the first day of radiotherapy) and radiotherapy
to the primary tumour and the lymph nodes involved on
FDG-PET-CT was given. In some cases, concurrently with radio-
therapy, two 21-day cycles of cisplatin (75 mg/m2 day 1) and eto-
poside (100 mg/m2 day 1–3) were administered. Individualised
iso-toxic accelerated radiotherapy with analogous normal tissue
constraints as those for sequential chemo-radiotherapy [11,12]
was given. In the first three weeks, 30 twice-daily fractions of
1.5 Gy were given, followed by once-daily fractions of 2 Gy [20]
until a mean lung dose of 19 Gy was reached, with a minimum
dose of 54 Gy and a maximum of 69 Gy. A mean radiation dose
to the tumour and the involved lymph nodes of 65 Gy delivered
in 5.5 weeks was given. This corresponds to a biological equivalent
of 72 Gy given in 36 daily fractions in 7.2 weeks.
For patients not treated with curative intent, the treatment was
left to the discretion of the treating physician. Both best supportive
care, including palliative radiotherapy, and chemotherapy, mainly
consisting of carboplatin and gemcitabine were given. Targeted
agents were not employed outside of clinical trials in the time peri-
ods studied in the present report.Follow-up
Patients were seen by the pulmonologist or the radiation oncol-
ogist the first weeks after the end of treatment until the acute side-
effects resolved to grade 1, and thereafter every three months the
230 Individualised radiotherapy stage III NSCLCfirst two years, every six months from year 3 to 5 and every year
after 5 years. A CT scan or an X-ray of the chest was done regularly
or on indication.Statistics
Patient characteristics were expressed as mean ± standard devi-
ation (SD) and their range. Differences between proportions were
calculated with Chi-square tests. Survival was calculated from
the date of diagnosis till death using the Kaplan–Meier method
with SPSS Statistics version 17.0. Median survival rates are ex-
pressed together with their 95% confidence intervals (CI). Survival
comparison between groups was calculated with the log-rank test.
Differences with a p-value <0.05 were considered significant.
The minimal follow-up time of all patients is 2 years. Survival
was updated in January 2011.
Results
From January 1, 2002 to December 31, 2008, 1002 patients with
stage III NSCLC were diagnosed. From this group, 64 had a T3N1 tu-
mour. Because this group is considered to be a surgical indication,
unless co-morbid conditions preclude this, these patients were
omitted from the present analysis.
Patient characteristics are summarised in Table 1.
Only 27.8% of the patients did not have co-morbidities, with
26.9% having Chronic Obstructive Pulmonary Disease (COPD),
18.3% a myocardial infarction, 16.4% hypertension, 14.3% anotherTable 1













Squamous cell carcinoma 31.9
Adenocarcinoma 24.1
Adenosquamous carcinoma 0.3
























* Mean ± Standard deviation and range (between brackets).malignancy in their medical history, 14.3% cardiac arrhythmias,
10.3% diabetes mellitus, and 10.0% peripheral arterial disease.
Two or more co-morbidities occurred in 37.5% of the patients,
17.5% had three or more co-morbidities, 6.6% four or more and
3.0% five co-morbidities.
Two-hundred and eight patients only received best supportive
care (BSC), which included any palliative radiotherapy, 203 pa-
tients were treated only with palliative chemotherapy, 179 pa-
tients with sequential chemotherapy and 60 Gy/30 fractions of
radiotherapy, 127 patients received sequential chemotherapy and
individualised isotoxic accelerated radiotherapy (INDAR), 66 con-
current chemotherapy and INDAR, 125 radiotherapy alone and
30 surgery with or without chemotherapy.
The number of cases with stage III NSCLC per year remained sta-
ble over time. In 2002, 138 new cases were diagnosed, in 2003:
133, in 2004: 134, in 2005: 136, in 2006: 128, in 2007: 131 and
in 2008: 138 (p = 0.49).
During the time period from 2002 to 2008, only the N-staged
distribution differed significantly. The proportion of patients with
mediastinal lymph node involvement increased from 89.1% in
2002 to 96.3% in 2008, with at the same time a shift from N2 to
N3 disease from 17% N3 in 2002 to 32% in 2008 (p = 0.02). Although
FDG-PET was used in all time periods, these changes coincide in
time with the introduction of the minimal invasive staging tools
such as endobronchial ultrasound (EBUS) and trans-oesophageal
(EUS) guided fine needle aspiration biopsy of mediastinal nodes
[21].
Neither the T-stage distribution (p = 0.45), nor the age
(p = 0.36), gender (p = 0.11), histology (p = 0.49), tumour location
(p = 0.27) or co-morbidity (p = 0.18) changed between 2002 and
2008. The distribution of these parameters within the different
treatment groups did not change significantly over time either.
The proportion of patients receiving BSC or palliative chemo-
therapy only decreased significantly (p < 0.001) over time. At the
same time, the percentage of patients receiving chemotherapy
and radiotherapy with curative intent increased from 24.6% in
2002 to 47.8% in 2008 (p < 0.001) (Table 2).
Surgery was only used in at maximum 5% of the patients
(Table 2). Surgical patients were also highly selected. Seventeen of
the thirty operated patients had a T4N0 tumour on the basis of mul-
tiple nodes in the same lung lobe. The stage distribution in the
remaining 13 surgical patients who also received induction chemo-
therapy was: T1N2: 1 patient, T2N2: 7 patients, T4N2: 3 patients,
T2N3: 2 patients.
The median survival of patients who only received BSC (n = 208)
was 2.8 months (95% CI 2.1–3.5), with a 1-year survival of 10.6%
and a 2-year survival of 2.9%.
When only chemotherapy (n = 203) was given, median survival
was 9.2 months (95% CI 7.8–10.6), and the 1-, 2-, and 5-year sur-
vival was 34.5%, 13.8% and 3.4%.
Sequential chemotherapy and radiotherapy to a dose of 60 Gy in
30 daily fractions (n = 179) lead to a median survival of
17.5 months (95% CI 15.0–20.0) and 1-, 2-, and 5-year survival
rates of 63.7%, 31.8% and 8.4%. Sequential chemotherapy and IN-
DAR (n = 129) resulted in a median survival of 23.6 months (95%
CI 19.1–28.1) and 1-, 2-, and 5-year survivals of 73.2%, 48.8% and
31.0%. The median survival of concurrent chemotherapy and
INDAR (n = 66) was not reached at the time of analysis, but the
1- and 2-year survival was 80.3% and 66.7%, with a maximal fol-
low-up of 34 months in this group (Fig. 1).
Radiotherapy alone (n = 125) resulted in a median survival of
12.0 months (95% CI 10.1–13.9), with a 1-, 2- and 5-year survival
of 51.2%, 25.6% and 14.9%.
The surgical group (n = 30) had a median survival of
16.6 months (95% CI 8.0–25.3) with a 1-year survival of 60%, 2-year
of 36.7% and 5-year of 25.7%.
Table 2
Evolution of the treatment over time.
Year 2002 2003 2004 2005 2006 2007 2008
Total number of patients 138 133 134 136 128 131 138
Treatment (% of total)
BSC/chemotherapy alone 47,1 48,1 44 47 40,6 42,7 37
Sequential chemotherapy and conventional RT 24,6 34,6 38 35,7 0 0 0
Sequential chemotherapy and INDAR 0 0 0 9,6 47,8 40,5 10
Concurrent chemotherapy and INDAR 0 0 0 0 0 0 37,8
RT alone 24,6 15,1 12,7 7,3 7,7 13,7 11,5
Surgery 3,7 2,2 5,3 0,8 3,9 3,1 3,7
Proportion of patients receiving chemo-radiotherapy 24.6 34.6 38 45.3 47.8 40.5 47.8
BSC, best supportive care; RT, radiotherapy; INDAR, individualised, isotoxic, accelerated radiot.
D. De Ruysscher et al. / Radiotherapy and Oncology 102 (2012) 228–233 231The differences in survival between the groups with BSC, che-
motherapy alone, sequential chemotherapy and 60 Gy and sequen-
tial chemotherapy and INDAR are all significant (p < 0.001). The
difference between sequential chemotherapy and INDAR and con-
current chemotherapy and INDAR is also significant (p = 0.004).
There were no significant differences between the surgical group
and sequential chemotherapy and 60 Gy conventional radiother-
apy (p = 0.15) and sequential chemotherapy and INDAR (p = 0.38).
However, the survival of concurrent chemotherapy and INDAR
was better than with surgery (p = 0.005).
Patients were divided in 6 age groups: below 50 years, from 50
to 59 years, from 60 to 64 years, from 65 to 70 years, from 71 to
74 years and over 74 years. Over these age groups, the significant
survival gain of sequential chemotherapy and INDAR over sequen-
tial chemotherapy and conventional radiotherapy and concurrent
chemotherapy and INDAR and sequential chemo-INDAR remained
(p < 0.001). However, as only four patients over 75 years received
concurrent chemo-radiation, results in this age group with respect
to the latter treatment should be viewed with caution.
Patients being treated in clinical trials or not did not have a sig-
nificantly different survival inside of each treatment group.
Discussion
Even with the current standard treatment of choice, concurrent
chemo-radiotherapy to a radiation dose of about 60 Gy in 30 frac-
tions, a median survival of about 24 months and a five-year sur-
vival of approximately 15% can be achieved in patients with
stage III NSCLC [5,6]. Sequential chemotherapy and 60 Gy in 30
fractions results in a median survival of 18 months and a 5-year
survival of 10% [5]. Moreover, a significant proportion of patients
is believed not to be able to receive this aggressive therapy, mostly
because of significant co-morbidity and frailty [10]. As an improve-
ment in local tumour control results in increased survival [5–7],
many groups have tried to increase the biological or the physical
radiation dose [6–9,11,12,22–24], the rationale being a dose–re-
sponse relation for NSCLC and radiotherapy [25]. A way to increase
on an individual basis the radiotherapy dose is to escalate the dose
up to normal tissue dose volume constraints and in an accelerated
schedule, so-called individualised iso-toxic accelerated radiother-
apy (INDAR) [11,12]. This strategy allows the safe delivery of bio-
logical doses that are comparable to more than 80 Gy in classical
2 Gy per day fractionation but with comparable toxicity to the
standard 60–66 Gy in 30–33 daily fractions [11,12,26]. INDAR is
achievable even in patients with very large tumour volumes. A
more optimal therapeutic ratio is thus achieved [26].
In this study, we demonstrate that the introduction of INDAR
delivered after chemotherapy increased both the median survival
as well as the 5-year survival rates of patients with stage III NSCLC.
Median survival increased from 17.5 months to 23.6 months and
the 5-year survival from 8.4% to 31%. The concurrent administra-
tion of INDAR with chemotherapy further increased the survival.Obviously, because this is not a randomised trial, the results
may be biased in favour of the more recently treated patients.
However, during the whole studied time frame from 2002 to
2008, the standard staging did not change. All patients in all time
periods were staged by means of FDG-PET scanning and received
appropriate brain imaging, either with a contrast-enhanced CT
scan or an MRI scan. Moreover, although the number of patients
with stage III NSCLC remained stable over time, the proportion
which was treated with curative intent and with chemo-radiation
increased in recent years. The distribution of co-morbidities, gen-
der, age and pathology did not change over time, thus supporting
that the improved results are neither due to improved staging
and hence stage migration nor to a better selection of patients. A
prescription bias can nevertheless not be ruled out, for the ultimate
treatment decision was made by multidisciplinary teams in differ-
ent referring hospitals. On the other hand, as the NCR/L is a popu-
lation-based cancer registry and covers more than 95% of all cancer
cases in the region, this reduces the likelihood for case selection
very much. The only time-trend observed was a shift to more N3
node involvement, possibly due to a higher use of EBUS and EUS.
A change over time in e.g. supportive care cannot be ruled out
and this may also have had an impact on the survival rates.
As Maastro clinic is the only radiotherapy centre in South and
Middle Limburg, The Netherlands, and only very few patients are
treated elsewhere, the present series is both a population based
and a single-centre study.
The results of sequential chemotherapy and conventional radio-
therapy and for surgery in our population-based study are in line
with literature [3–5,27,28]. The treatment with which INDAR is
compared is thus a realistic benchmark. Of interest is also that
about 15% of these PET-staged patients, who were only treated
with local radiotherapy, had a 5-year survival of about 15%. This
underscores the need for further development of prognostic tools
to identify individual patients who are likely to benefit from a fur-
ther intensification of their local treatment [29–32]. It should not
be forgotten that at the time period in this trial, stage III included
‘‘wet’’ T4 tumours with malignant pleuritis or pericarditis. These
patients were therefore included in this analysis and may also ex-
plain the relatively high proportion of stage III patients being trea-
ted palliatively.
It should be acknowledged that the obtained 5-year survival
rates, which are amongst the highest reported in literature, cannot
be compared straightforward with other series because it cannot
be excluded that the meticulous staging we used may have im-
proved the survival as well.
Recently, there has been a wealth of publications pointing to
improvements of all parts of the chain in lung cancer radiotherapy,
going from target volume delineation and for the identification of
prognosticators before and during treatment for tumour response
and normal tissue complications using multi-factorial parameters
[33–42] and the development of dose-painting trials [43]. These
developments, together with the observation that intensive
Seq. chemo-conventional RT             179    114     57       30      19  15
Seq. chemo-INDAR                            129     94      62       43    26          6

















Fig. 1. Overall survival of stage III NSCLC patients treated with sequential chemotherapy and radiotherapy (60 Gy/30 fractions/6 weeks) (n = 179, solid line), sequential
chemotherapy and individualised isotoxic accelerated radiotherapy (n = 129, INDAR) (dotted line) and concurrent chemotherapy and INDAR (n = 66, semi-dotted line).
Sequential chemo-radiotherapy (60 Gy/30 fractions/6 weeks vs. sequential INDAR: p < 0.001); sequential INDAR vs. concurrent INDAR; p = 0.004.
232 Individualised radiotherapy stage III NSCLCchemo-radiotherapy has no influence on the long-term quality of
life of lung cancer patients [44] and may even improve dyspnoea
[11,45] support the use of high-dose radiotherapy in lung cancer
patients further.
INDAR is obviously more costly and less convenient than once-
daily fractionation. A study with individualised, accelerated, iso-
toxic radiotherapy using moderate once-daily hypofractionation
is therefore being tested in an ongoing trial.
In summary, the results of this prospective population-based
registry show that the introduction of individualised isotoxic accel-
erated radiotherapy was associated with improved long-term sur-
vival of patients with stage III NSCLC.Conflict of interest statement
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